CELG Dividend History & Description — Bristol Myers Squibb Co.
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s pharmaceutical products include chemically-synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor T-cell therapies. Co.'s primary product includes Eliquis® - Eliquis (apixaban), which is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy. When considering the Bristol Myers Squibb Co. stock dividend history, we have taken known splits into account, such that the CELG dividend history is presented on a split-adjusted ("apples to apples") basis. Bristol Myers Squibb Co. dividend history is presented both in graphical/chart form, and as a CELG dividend history data table along the right-hand column.